Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo A tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

NCT00817986
View directory record Official record
Conditions
Back Pain
Interventions
Arbaclofen placarbil, 20 mg, Placebo, Arbaclofen placarbil, 30 mg, Arbaclofen placarbil, 40 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Litchfield Park, Arizona • Anaheim, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

NCT03192488
View directory record Official record
Conditions
Hypoxia, Altitude
Interventions
Cetirizine, Placebo oral capsule, Hypoxia
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

NCT01360554
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
107
States / cities
Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

Maxigesic 325 Acute Dental Pain Study

NCT01420653
View directory record Official record
Conditions
Dental Pain
Interventions
Maxigesic 325, Acetaminophen, Ibuprofen, Placebo
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

NCT00129272
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder
Interventions
Bupropion-SR, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
12 Years to 25 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

NCT00683657
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Escondido, California • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SUVN-502, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

NCT00637273
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Peoria, Arizona • Artesia, California • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Early Phase 1 Interventional Results available

Sildenafil To Prevent Clot

NCT03199612
View directory record Official record
Conditions
Thrombosis, Hemolysis
Interventions
Sildenafil, Placebo Oral Tablet
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT04129619
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
ORP-101, Placebo
Drug
Lead sponsor
OrphoMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

NCT00671502
View directory record Official record
Conditions
Lower Back Pain
Interventions
Carisoprodol SR, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

NCT00401830
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 1, 2026, 4:49 AM EDT
Recruiting Phase 1 Interventional

SGLTi, Hepatic Glucose Production and Ketogenesis

NCT05960656
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, 20 mg BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Garden Grove, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 1, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available

Fasiglifam 25 mg BID vs 50 mg QD

NCT01982253
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Fasiglifam, Placebo to fasiglifam
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Goodyear, Arizona • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 1, 2026, 4:49 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults

NCT02261519
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug · Other
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 45 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 1, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

NCT06480383
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
Not listed
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Glendale, California • Imperial, California • Lemon Grove, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

NCT00926575
View directory record Official record
Conditions
Acute Gastrointestinal Graft vs Host Disease
Interventions
oral beclomethasone 17,21-dipropionate, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

NCT04218240
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Pregabalin 200 MG capsules, Placebo oral tablet, Lofexidine 0.18Mg Tab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

Ictal and Interictal Inflammatory Markers in Migraine

NCT01138150
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 1, 2026, 4:49 AM EDT
Completed Not applicable Interventional

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 1, 2026, 4:49 AM EDT